Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 18, 2024 - Issue
Submit an article Journal homepage
49
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Validation of Core Ingredients and Molecular Mechanism of Cinobufotalin Injection Against Liver Cancer

Shipeng Chen1 NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People’s Republic of China;2 Cancer Research Institute, Central South University, Changsha, 410078, People’s Republic of China;3 The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People’s Republic of ChinaView further author information
,
Mengna Li1 NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People’s Republic of China;2 Cancer Research Institute, Central South University, Changsha, 410078, People’s Republic of China;3 The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People’s Republic of ChinaView further author information
,
Changning Xue1 NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People’s Republic of China;2 Cancer Research Institute, Central South University, Changsha, 410078, People’s Republic of China;3 The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People’s Republic of ChinaView further author information
,
Xiangting Zhou1 NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People’s Republic of China;2 Cancer Research Institute, Central South University, Changsha, 410078, People’s Republic of China;3 The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People’s Republic of ChinaView further author information
,
Jianxia Wei1 NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People’s Republic of China;2 Cancer Research Institute, Central South University, Changsha, 410078, People’s Republic of China;3 The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People’s Republic of ChinaView further author information
,
Lemei Zheng1 NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People’s Republic of China;2 Cancer Research Institute, Central South University, Changsha, 410078, People’s Republic of China;3 The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People’s Republic of ChinaView further author information
,
Yumei Duan1 NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People’s Republic of China;2 Cancer Research Institute, Central South University, Changsha, 410078, People’s Republic of China;3 The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People’s Republic of ChinaView further author information
,
Hongyu Deng1 NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People’s Republic of ChinaView further author information
,
Faqing Tang1 NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0001-5794-4975View further author information
ORCID Icon,
Wei Xiong1 NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People’s Republic of China;2 Cancer Research Institute, Central South University, Changsha, 410078, People’s Republic of China;3 The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People’s Republic of ChinaView further author information
,
Bo Xiang1 NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People’s Republic of China;2 Cancer Research Institute, Central South University, Changsha, 410078, People’s Republic of China;3 The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People’s Republic of ChinaView further author information
&
Ming Zhou1 NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People’s Republic of China;2 Cancer Research Institute, Central South University, Changsha, 410078, People’s Republic of China;3 The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
 show all
Pages 1321-1338 | Received 27 Oct 2023, Accepted 10 Apr 2024, Published online: 24 Apr 2024

References

  • Brown ZJ, Tsilimigras DI, Ruff SM, et al. Management of Hepatocellular Carcinoma: a Review. JAMA Surgery. 2023;158(4):410–420. doi:10.1001/jamasurg.2022.7989
  • Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516–537. doi:10.1016/j.jhep.2023.03.017
  • Liu Z, Suo C, Mao X, et al. Global incidence trends in primary liver cancer by age at diagnosis, sex, region, and etiology, 1990-2017. Cancer. 2020;126(10):2267–2278. doi:10.1002/cncr.32789
  • Ganesan P, Kulik LM. Hepatocellular Carcinoma: new Developments. Clin Liver Dis. 2023;27(1):85–102. doi:10.1016/j.cld.2022.08.004
  • Stępniak J, Krawczyk-Lipiec J, Lewiński A, Karbownik-Lewińska M. Sorafenib versus Lenvatinib Causes Stronger Oxidative Damage to Membrane Lipids in Noncancerous Tissues of the Thyroid, Liver, and Kidney: effective Protection by Melatonin and Indole-3-Propionic Acid. Biomedicines. 2022;10(11):2890. doi:10.3390/biomedicines10112890
  • Guo N, Miao Y, Sun M. Transcatheter hepatic arterial chemoembolization plus cinobufotalin injection adjuvant therapy for advanced hepatocellular carcinoma: a meta-analysis of 27 trials involving 2079 patients. Onco Targets Ther. 2018;11:8835–8853. doi:10.2147/ott.S182840
  • Wei J, Liu Z, He J, et al. Traditional Chinese medicine reverses cancer multidrug resistance and its mechanism. Clin Translational Oncol. 2022;24(3):471–482. doi:10.1007/s12094-021-02716-4
  • Wang Z, Qi F, Cui Y, et al. An update on Chinese herbal medicines as adjuvant treatment of anticancer therapeutics. Biosci Trends. 2018;12(3):220–239. doi:10.5582/bst.2018.01144
  • Pharmacopoeia CC. Pharmacopoeia of the People’s Republic of China. 2010.
  • Song GP. Effect of Cinobufagin Injection on Prevention of Recurrence of Primary Liver Cancer with Radical Resection. Chin J Exp Traditional Med Formulae. 2012.
  • Zhang P, Zhang D, Zhou W, et al. Network pharmacology: towards the artificial intelligence-based precision traditional Chinese medicine. Briefings Bioinf. 2023;25(1):675.
  • Safran M, Rosen N, Twik M, et al. The GeneCards Suite. In: Abugessaisa I, Kasukawa T, editors. Practical Guide to Life Science Databases. Springer Nature Singapore; 2021. 27–56.
  • Lee L, Wang K, Li G, et al. Liverome: a curated database of liver cancer-related gene signatures with self-contained context information. BMC Genomics. 2011;12 Suppl 3(Suppl 3):S3. doi:10.1186/1471-2164-12-s3-s3
  • Tang G, Cho M, Wang X. OncoDB: an interactive online database for analysis of gene expression and viral infection in cancer. Nucleic Acids Res. 2022;50(D1):D1334–d1339. doi:10.1093/nar/gkab970
  • Fang S, Dong L, Liu L, et al. HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine. Nucleic Acids Res. 2021;49(D1):D1197–d1206. doi:10.1093/nar/gkaa1063
  • Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47(W1):W357–w364. doi:10.1093/nar/gkz382
  • Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717. doi:10.1038/srep42717
  • Otasek D, Morris JH, Bouças J, Pico AR, Demchak B. Cytoscape Automation: empowering workflow-based network analysis. Genome Biol. 2019;20(1):185. doi:10.1186/s13059-019-1758-4
  • Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1):D638–d646. doi:10.1093/nar/gkac1000
  • Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst. Biol. 2014;8 Suppl 4(Suppl 4):S11. doi:10.1186/1752-0509-8-s4-s11
  • Sherman BT, Hao M, Qiu J, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):W216–w221. doi:10.1093/nar/gkac194
  • Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–w560. doi:10.1093/nar/gkz430
  • Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002
  • Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–461. doi:10.1002/jcc.21334
  • Ibrahim AA, Kareem MM, Al-Noor TH, et al. Pt(II)-Thiocarbohydrazone Complex as Cytotoxic Agent and Apoptosis Inducer in Caov-3 and HT-29 Cells through the P53 and Caspase-8 Pathways. Pharmaceuticals. 2021;14:6.
  • Sun S, Zheng G, Zhou D, et al. Emodin Interferes With Nitroglycerin-Induced Migraine in Rats Through CGMP-PKG Pathway. Front Pharmacol. 2021;12:758026. doi:10.3389/fphar.2021.758026
  • Dwivedi AK, Mallawaarachchi I, Alvarado LA. Analysis of small sample size studies using nonparametric bootstrap test with pooled resampling method. Stat Med. 2017;36(14):2187–2205. doi:10.1002/sim.7263
  • Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. doi:10.1016/s0092-8674(00)81683-9
  • Hsin KY, Ghosh S, Kitano H. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology. PLoS One. 2013;8(12):e83922. doi:10.1371/journal.pone.0083922
  • Shen JJ. The clinical effect of Cinobufagin injection by transcatheter arterial chemoembolization(TACE) combined with intravenous on treating primary liver cancer(PLC). J Clin Hepatol. 2009;207–209.
  • Wei J, Li M, Xue C, et al. Understanding the roles and regulation patterns of circRNA on its host gene in tumorigenesis and tumor progression. J Exp Clin Cancer Res. 2023;42(1):86. doi:10.1186/s13046-023-02657-6
  • Li M, Wei Y, Liu Y, et al. BRD7 inhibits enhancer activity and expression of BIRC2 to suppress tumor growth and metastasis in nasopharyngeal carcinoma. Cell Death Dis. 2023;14(2):121. doi:10.1038/s41419-023-05632-3
  • Liu K, Zheng M, Lu R, et al. The role of CDC25C in cell cycle regulation and clinical cancer therapy: a systematic review. Can Cell Inter. 2020;20:213. doi:10.1186/s12935-020-01304-w
  • Islam B, Yu HY, Duan TQ, et al. Cell cycle kinases (AUKA, CDK1, PLK1) are prognostic biomarkers and correlated with tumor-infiltrating leukocytes in HBV related HCC. J Biomol Struct Dyn. 2023;41(21):11845–11861. doi:10.1080/07391102.2022.2164056
  • de Groot CO, Hsia JE, Anzola JV, et al. A Cell Biologist’s Field Guide to Aurora Kinase Inhibitors. Front Oncol. 2015;5:285. doi:10.3389/fonc.2015.00285
  • Infante JR, Cassier PA, Gerecitano JF, et al. A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res. 2016;22(23):5696–5705. doi:10.1158/1078-0432.Ccr-16-1248
  • Rolf MG, Curwen JO, Veldman-Jones M, et al. In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspectives. 2015;3(5):e00175. doi:10.1002/prp2.175
  • Jin X, Wang J, Zou S, et al. Cinobufagin Triggers Defects in Spindle Formation and Cap-Dependent Translation in Liver Cancer Cells by Inhibiting the AURKA-mTOR-eIF4E Axis. Am J Chin Med. 2020;48(3):651–678. doi:10.1142/s0192415x20500330
  • Liu JH, Yang HL, Deng ST, et al. The small molecule chemical compound cinobufotalin attenuates resistance to DDP by inducing ENKUR expression to suppress MYH9-mediated c-Myc deubiquitination in lung adenocarcinoma. Acta Pharmacol Sin. 2022;43(10):2687–2695. doi:10.1038/s41401-022-00890-x
  • Meng H, Shen M, Li J, et al. Novel SREBP1 inhibitor cinobufotalin suppresses proliferation of hepatocellular carcinoma by targeting lipogenesis. Eur J. Pharmacol. 2021;906:174280. doi:10.1016/j.ejphar.2021.174280
  • Han Q, Zhang C, Zhang Y, Li Y, Wu L, Sun X. Bufarenogin induces intrinsic apoptosis via Bax and ANT cooperation. Pharmacol Res Perspectives. 2021;9(1):e00694. doi:10.1002/prp2.694
  • Nero TL, Morton CJ, Holien JK, Wielens J, Parker MW. Oncogenic protein interfaces: small molecules, big challenges. Nat Rev Cancer. 2014;14(4):248–262. doi:10.1038/nrc3690
  • Weigelt J, McBroom-Cerajewski LD, Schapira M, Zhao Y, Arrowsmith CH. Structural genomics and drug discovery: all in the family. Curr Opin Chem Biol. 2008;12(1):32–39. doi:10.1016/j.cbpa.2008.01.045
  • Arkin MR, Tang Y, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol. 2014;21(9):1102–1114. doi:10.1016/j.chembiol.2014.09.001
  • Zhang G, Zhang J, Gao Y, Li Y. Strategies for targeting undruggable targets. Expert Opin Drug Discov. 2022;17(1):55–69. doi:10.1080/17460441.2021.1969359
  • Li Y, Zhang J, Gao W, et al. Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2. Int J Mol Sci. 2015;16(5):9314–9340. doi:10.3390/ijms16059314
  • Hardcastle IR, Golding BT, Griffin RJ. Designing inhibitors of cyclin-dependent kinases. Annu Rev Pharmacol Toxicol. 2002;42:325–348. doi:10.1146/annurev.pharmtox.42.090601.125940
  • Zhang MS, Cui JD, Lee D, et al. Hypoxia-induced macropinocytosis represents a metabolic route for liver cancer. Nat Commun. 2022;13(1):954. doi:10.1038/s41467-022-28618-9
  • Liu W, Zhou X, Yao Q, et al. In situ expansion and reprogramming of Kupffer cells elicit potent tumoricidal immunity against liver metastasis. J Clin Invest. 2023;133(8).
  • Arifin WN, Zahiruddin WM. Sample Size Calculation in Animal Studies Using Resource Equation Approach. Malaysian j med sci. 2017;24(5):101–105. doi:10.21315/mjms2017.24.5.11
  • Dai CL, Zhang RJ, An P, Deng YQ, Rahman K, Zhang H. Cinobufagin: a promising therapeutic agent for cancer. J Pharm Pharmacol. 2023;75(9):1141–1153. doi:10.1093/jpp/rgad059

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.